Antisense Therapeutics Limited Stock Book Value Per Share
Antisense Therapeutics Limited fundamentals help investors to digest information that contributes to Antisense Therapeutics' financial success or failures. It also enables traders to predict the movement of Antisense Pink Sheet. The fundamental analysis module provides a way to measure Antisense Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Antisense Therapeutics pink sheet.
Antisense |
Antisense Therapeutics Limited Company Book Value Per Share Analysis
Antisense Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Antisense Therapeutics Book Value Per Share | 0.03 X |
Most of Antisense Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Antisense Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Antisense Therapeutics Limited is about 0.032 times. This is 101.88% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The book value per share for all United States stocks is 100.0% higher than that of the company.
Antisense Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Antisense Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Antisense Therapeutics could also be used in its relative valuation, which is a method of valuing Antisense Therapeutics by comparing valuation metrics of similar companies.Antisense Therapeutics is currently under evaluation in book value per share category among its peers.
Antisense Fundamentals
Return On Equity | -0.43 | |||
Return On Asset | -0.25 | |||
Operating Margin | (3.28) % | |||
Current Valuation | 27.82 M | |||
Shares Outstanding | 669.04 M | |||
Shares Owned By Insiders | 19.30 % | |||
Shares Owned By Institutions | 4.93 % | |||
Price To Earning | (3.62) X | |||
Price To Book | 3.05 X | |||
Price To Sales | 24.46 X | |||
Revenue | 1.78 M | |||
Gross Profit | 1.71 M | |||
EBITDA | (7.52 M) | |||
Net Income | (5.81 M) | |||
Cash And Equivalents | 19.23 M | |||
Cash Per Share | 0.03 X | |||
Total Debt | 227.4 K | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 19.14 X | |||
Book Value Per Share | 0.03 X | |||
Cash Flow From Operations | (7.81 M) | |||
Earnings Per Share | (0.01) X | |||
Number Of Employees | 12 | |||
Beta | 0.67 | |||
Market Capitalization | 41.78 M | |||
Total Asset | 22.44 M | |||
Retained Earnings | (53 M) | |||
Working Capital | 4 M | |||
Current Asset | 5 M | |||
Current Liabilities | 1000 K | |||
Net Asset | 22.44 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Antisense Pink Sheet
If you are still planning to invest in Antisense Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Antisense Therapeutics' history and understand the potential risks before investing.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |